Can Fite BiopharmaCANF -15.55%55 Return-on-Tangible-Asset is -114.94% as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $6.33 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,413 Biotechnology companies, Can Fite Biopharma ranks worse than 81.39% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Can Fite Biopharma's annualizedNet Income for the quarter that ended in Dec. 2025 was $-9.90 Mil. Can Fite Biopharma's average total tangible assets for the quarter that ended in Dec. 2025 was $8.62 Mil. Therefore, Can Fite Biopharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -114.94%.
The historical rank and industry rank for Can Fite Biopharma's Return-on-Tangible-Asset or its related term are showing as below:
CANF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -163.23 Med: -83.45 Max: -59.47
Current: -111.87
During the past 13 years, Can Fite Biopharma's highest Return-on-Tangible-Asset was -59.47%. The lowest was -163.23%. And the median was -83.45%.
CANF's Return-on-Tangible-Asset is ranked worse than 81.39% of 1413
companies
in the Biotechnology industry
Industry Median: -35.57
vs CANF: -111.87
Can Fite Biopharma (AMEX:CANF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Can Fite Biopharma Return-on-Tangible-Asset Related Terms
Can Fite Biopharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -114.94% mean?
Can Fite Biopharma (CANF) has a Return-on-Tangible-Asset of -114.94% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #1150 out of 1413 companies in the Biotechnology industry, placing it in the top 81.4%.
Is Can Fite Biopharma's Return-on-Tangible-Asset too high?
Can Fite Biopharma's current Return-on-Tangible-Asset is -114.94%. Based on the distribution chart, Can Fite Biopharma ranks #1150 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #1150 out of 1413 companies for Return-on-Tangible-Asset. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current Return-on-Tangible-Asset is -114.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.33, compared to a current price of $3.91 — trading 38.2% below its estimated fair value. The current Return-on-Tangible-Asset is -114.94%. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Return-on-Tangible-Asset is -114.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.91 is trading 38.2% below its estimated GF Value™ of $6.33.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Return-on-Tangible-Asset: -114.94%
GF Value™: $6.33 vs. price of $3.91 (38.2% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
